COPENHAGEN, July 2 (Reuters) - Danish pharmaceuticals group H. Lundbeck A/S (LUN.CO) said on Thursday:
* A Phase II clinical trial of its Lu AA24530 candidate drug for treatment of major depressive disorder showed positive results.
* "These findings demonstrate the potential value of Lu AA24530 in the treatment of major depressive disorders."
(Reporting by Copenhagen newsroom)
© Thomson Reuters 2009 All rights reserved
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Labs |
Journalism Handbook |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
